[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HRP20090340T1 - Derivati 5-fenil-4-metil-tiazol-2-il-amina kao inhibitori enzima fosfatidilinozitol 3-kinaza (pi3) za liječenje upalnih bolesti dišnih puteva - Google Patents

Derivati 5-fenil-4-metil-tiazol-2-il-amina kao inhibitori enzima fosfatidilinozitol 3-kinaza (pi3) za liječenje upalnih bolesti dišnih puteva

Info

Publication number
HRP20090340T1
HRP20090340T1 HR20090340T HRP20090340T HRP20090340T1 HR P20090340 T1 HRP20090340 T1 HR P20090340T1 HR 20090340 T HR20090340 T HR 20090340T HR P20090340 T HRP20090340 T HR P20090340T HR P20090340 T1 HRP20090340 T1 HR P20090340T1
Authority
HR
Croatia
Prior art keywords
thiazol
phenyl
methyl
phosphatidylinositol
airways
Prior art date
Application number
HR20090340T
Other languages
English (en)
Croatian (hr)
Inventor
C. Bloomfield G.
Bruce Ian
Fox Hayler Judy
Leblanc C.
M. Le Grand D.
Mccarthy Clive
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HRP20090340T1 publication Critical patent/HRP20090340T1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/48—Acylated amino or imino radicals by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof, e.g. carbonylguanidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HR20090340T 2003-08-28 2004-08-27 Derivati 5-fenil-4-metil-tiazol-2-il-amina kao inhibitori enzima fosfatidilinozitol 3-kinaza (pi3) za liječenje upalnih bolesti dišnih puteva HRP20090340T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0320197.7A GB0320197D0 (en) 2003-08-28 2003-08-28 Organic compounds
PCT/EP2004/009586 WO2005021519A2 (en) 2003-08-28 2004-08-27 5-phenyl-4-methyl-thiazol-2-yl-amine derivatives as inhibitors of phosphatidylinositol 3 kinase enzymes (pi3) for the treatment of inflammatory airway diseases

Publications (1)

Publication Number Publication Date
HRP20090340T1 true HRP20090340T1 (hr) 2009-07-31

Family

ID=28686509

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20090340T HRP20090340T1 (hr) 2003-08-28 2004-08-27 Derivati 5-fenil-4-metil-tiazol-2-il-amina kao inhibitori enzima fosfatidilinozitol 3-kinaza (pi3) za liječenje upalnih bolesti dišnih puteva

Country Status (33)

Country Link
US (3) US7902375B2 (xx)
EP (1) EP1689391B1 (xx)
JP (1) JP4574618B2 (xx)
KR (1) KR100774038B1 (xx)
CN (1) CN1838953B (xx)
AR (1) AR045510A1 (xx)
AT (1) ATE429225T1 (xx)
AU (1) AU2004268050B2 (xx)
BR (1) BRPI0413934A (xx)
CA (1) CA2533175A1 (xx)
CY (1) CY1109227T1 (xx)
DE (1) DE602004020793D1 (xx)
DK (1) DK1689391T3 (xx)
EC (1) ECSP066383A (xx)
ES (1) ES2323000T3 (xx)
GB (1) GB0320197D0 (xx)
HR (1) HRP20090340T1 (xx)
IL (1) IL173035A0 (xx)
IS (1) IS2690B (xx)
MA (1) MA28007A1 (xx)
MX (1) MXPA06002217A (xx)
MY (1) MY135050A (xx)
NO (1) NO20061406L (xx)
NZ (1) NZ545139A (xx)
PE (1) PE20050872A1 (xx)
PL (1) PL1689391T3 (xx)
PT (1) PT1689391E (xx)
RU (1) RU2382783C2 (xx)
SI (1) SI1689391T1 (xx)
TN (1) TNSN06064A1 (xx)
TW (1) TWI347941B (xx)
WO (1) WO2005021519A2 (xx)
ZA (1) ZA200600415B (xx)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
WO2005118543A1 (ja) * 2004-06-03 2005-12-15 Ono Pharmaceutical Co., Ltd. キナーゼ阻害薬およびその用途
WO2006037468A1 (en) * 2004-09-30 2006-04-13 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Hiv reverse transcriptase inhibitors
BRPI0611029A2 (pt) * 2005-05-24 2010-08-10 Serono Lab derivados de tiazol e uso dos mesmos
US7799814B2 (en) 2005-05-24 2010-09-21 Merck Serono S.A. Thiazole derivatives and use thereof
BRPI0615233A2 (pt) 2005-08-26 2011-05-10 Serono Lab derivados de pirazina e uso dos mesmos como inibidores p13k
GB0525671D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
CA2637530A1 (en) * 2006-01-18 2007-09-07 Siena Biotech S.P.A. Modulators of alpha7 nicotinic acetylcholine receptors and therapeutic uses thereof
GB0608854D0 (en) * 2006-05-04 2006-06-14 Chroma Therapeutics Ltd P13 kinase inhibitors
GB0608823D0 (en) * 2006-05-04 2006-06-14 Chroma Therapeutics Ltd Inhibitors of P13 kinase
GB0610243D0 (en) * 2006-05-23 2006-07-05 Novartis Ag Organic compounds
GB0612630D0 (en) * 2006-06-26 2006-08-02 Novartis Ag Organic compounds
NZ578229A (en) 2007-02-22 2012-02-24 Merck Serono Sa Quinoxaline compounds and use thereof
US8158677B2 (en) 2007-06-01 2012-04-17 The Trustees Of Princeton University Treatment of viral infections by modulation of host cell metabolic pathways
US20100298286A1 (en) * 2007-12-20 2010-11-25 Novartis Ag Organic Compounds
WO2009080694A1 (en) 2007-12-20 2009-07-02 Novartis Ag Thiazole derivatives used as pi 3 kinase inhibitors
UA104147C2 (uk) * 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
CN101684106B (zh) * 2008-09-22 2013-06-12 北京摩力克科技有限公司 噻唑鎓盐类化合物及其治疗蛋白老化相关疾病的用途
KR20110115160A (ko) 2009-02-12 2011-10-20 메르크 세로노 에스. 에이. 2-모르폴리노-피리도〔3,2-ｄ〕피리미딘
TWI516487B (zh) * 2009-04-30 2016-01-11 葛蘭素集團有限公司 新穎化合物、其醫藥組合物及作為激酶活性抑制劑之用途
EP2440556A1 (en) * 2009-06-10 2012-04-18 Vertex Pharmaceuticals Incorporated Inhibitors of phosphatidylinositol 3-kinase
US8293753B2 (en) * 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
ES2432671T3 (es) 2009-07-02 2013-12-04 Novartis Ag 2-carboxamida cicloamino ureas útiles como inhibidores de PI3K
WO2011048936A1 (ja) 2009-10-19 2011-04-28 大正製薬株式会社 アミノチアゾール誘導体
CN102695710B (zh) 2009-11-13 2015-08-19 默克雪兰诺有限公司 三环吡唑胺衍生物
AR080643A1 (es) 2010-02-03 2012-04-25 Signal Pharm Llc Identificacion de la mutacion de lkb1 como un biomarcador predictivo para la sensibilidad a inhibidores de la tor quinasa
GB201018124D0 (en) * 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
WO2013018733A1 (ja) * 2011-07-29 2013-02-07 富士フイルム株式会社 １，５－ナフチリジン誘導体又はその塩
US20130158023A1 (en) 2011-08-03 2013-06-20 Signal Pharmaceuticals, Llc Identification of gene expression as a predictive biomarker for lkb1 status
US9309236B2 (en) 2011-10-05 2016-04-12 The Board Of Trustees Of The Leland Stanford Junior University PI-kinase inhibitors with broad spectrum anti-infective activity
US9926309B2 (en) 2011-10-05 2018-03-27 The Board Of Trustees Of The Leland Stanford Junior University Pi-kinase inhibitors with anti-infective activity
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
MX368286B (es) 2013-04-17 2019-09-27 Signal Pharm Llc Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto de quinazolinona 5-sustituida para tratar cancer.
EP2986298A1 (en) 2013-04-17 2016-02-24 Signal Pharmaceuticals, LLC Treatment of cancer with dihydropyrazino-pyrazines
MX374749B (es) 2013-04-17 2025-03-06 Signal Pharm Llc Terapia de combinacion que comprende un inhibidor de tor cinasa y un analogo de citidina para tratar cancer.
HK1221951A1 (zh) 2013-04-17 2017-06-16 西格诺药品有限公司 有關1-乙基-7-(2-甲基-6-(1H-1，2，4-三唑-3-基)吡啶-3-基)-3，4-二氫吡嗪並[2，3-b]吡嗪-2(1H)-酮的藥物製劑、程序、固體形式和使用方法
SG10201801965RA (en) 2013-04-17 2018-04-27 Signal Pharm Llc Treatment of cancer with dihydropyrazino-pyrazines
EP2986319A1 (en) 2013-04-17 2016-02-24 Signal Pharmaceuticals, LLC Combination therapy comprising a tor kinase inhibitor and n-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide for treating cancer
WO2014172431A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
CA3143529A1 (en) 2013-05-29 2014-12-04 Signal Pharmaceuticals, Llc Pharmaceutical compositions 0f 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
US9512129B2 (en) 2014-04-16 2016-12-06 Signal Pharmaceuticals, Llc Solid forms comprising 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one and a coformer
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
CN107847480B (zh) * 2015-03-23 2021-06-25 墨尔本大学 呼吸性疾病的治疗
HK1252693A1 (zh) 2015-06-30 2019-05-31 Dana Farber Cancer Institute, Inc. Egfr抑制劑及其使用方法
ES3010661T3 (en) 2016-02-26 2025-04-04 Univ Leland Stanford Junior Pi-kinase inhibitors with anti-infective activity
JOP20190052A1 (ar) * 2016-09-22 2019-03-21 Astrazeneca Ab 5-[2-(بيريدين-2-يلامينو )-3،1 ثيازول-5-يال]-3،2 – ثنائي هيدرو- 1h- إيزوإندول 1--مشتق واحد واستخدامها كمثبطات مزدوجة للدلتا وغاما فوسفاتيديلينوسيتول 3-كيناز
IL271491B2 (en) 2017-06-22 2023-09-01 Celgene Corp Treatment of carcinoma of the liver characterized by hepatitis b virus infection
EP4114529A1 (en) 2020-03-03 2023-01-11 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
US12157732B2 (en) 2021-08-25 2024-12-03 PIC Therapeutics, Inc. eIF4E inhibitors and uses thereof
CA3229560A1 (en) 2021-08-25 2023-03-02 Christopher L. Vandeusen Eif4e inhibitors and uses thereof
CN116874442A (zh) * 2023-07-27 2023-10-13 武汉呈瑞生物医药科技有限公司 一种有机化合物及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1279531A1 (ru) * 1983-02-14 1986-12-23 Nippon Soda Co "cпocoб пoлучehия пpoизboдhыx tиaзoлиhotpиaзиha"
EP0589985A1 (en) * 1991-06-21 1994-04-06 Boehringer Mannheim Italia S.P.A. 2-amino-4-aryl-thiazoles with antiasthmatic and anti-inflammatory activities on the respiratory tract
GB9823873D0 (en) * 1998-10-30 1998-12-30 Pharmacia & Upjohn Spa 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents
EP1218376B1 (en) 1999-09-10 2005-11-09 Merck & Co., Inc. Tyrosine kinase inhibitors
US6667300B2 (en) * 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
EP1294690A2 (en) * 2000-06-21 2003-03-26 Bristol-Myers Squibb Pharma Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
JP2004509857A (ja) * 2000-07-26 2004-04-02 ブリストル−マイヤーズ　スクイブ　カンパニー サイクリン依存性キナーゼのｎ−［５−［［［５−アルキル−２−オキサゾリル］メチル］チオ］−２−チアゾリル］カルボキサミドインヒビター
WO2003015778A1 (en) * 2001-08-17 2003-02-27 Merck & Co., Inc. Tyrosine kinase inhibitors
MY156407A (en) 2002-02-28 2016-02-26 Novartis Ag 5-phenylthiazole derivatives and use as p13 kinase inhibitors

Also Published As

Publication number Publication date
EP1689391B1 (en) 2009-04-22
US20110124693A1 (en) 2011-05-26
ATE429225T1 (de) 2009-05-15
CN1838953A (zh) 2006-09-27
TW200517386A (en) 2005-06-01
CN1838953B (zh) 2011-02-02
AR045510A1 (es) 2005-11-02
TNSN06064A1 (en) 2007-10-03
JP2007504109A (ja) 2007-03-01
MY135050A (en) 2008-01-31
TWI347941B (en) 2011-09-01
PT1689391E (pt) 2009-06-19
NZ545139A (en) 2009-11-27
IL173035A0 (en) 2006-06-11
CA2533175A1 (en) 2005-03-10
ZA200600415B (en) 2007-12-27
RU2006109545A (ru) 2007-10-10
HK1093688A1 (en) 2007-03-09
JP4574618B2 (ja) 2010-11-04
US20080280871A1 (en) 2008-11-13
IS2690B (is) 2010-10-15
WO2005021519A2 (en) 2005-03-10
ES2323000T3 (es) 2009-07-03
US7902375B2 (en) 2011-03-08
MA28007A1 (fr) 2006-07-03
GB0320197D0 (en) 2003-10-01
ECSP066383A (es) 2006-08-30
US20110124624A1 (en) 2011-05-26
IS8372A (is) 2006-03-24
MXPA06002217A (es) 2006-04-27
DK1689391T3 (da) 2009-07-27
KR100774038B1 (ko) 2007-11-06
WO2005021519A3 (en) 2005-05-12
PL1689391T3 (pl) 2009-09-30
RU2382783C2 (ru) 2010-02-27
KR20060060704A (ko) 2006-06-05
SI1689391T1 (sl) 2009-08-31
EP1689391A2 (en) 2006-08-16
NO20061406L (no) 2006-08-25
AU2004268050B2 (en) 2006-11-16
PE20050872A1 (es) 2005-11-22
BRPI0413934A (pt) 2006-10-24
DE602004020793D1 (de) 2009-06-04
CY1109227T1 (el) 2014-07-02
AU2004268050A1 (en) 2005-03-10

Similar Documents

Publication Publication Date Title
HRP20090340T1 (hr) Derivati 5-fenil-4-metil-tiazol-2-il-amina kao inhibitori enzima fosfatidilinozitol 3-kinaza (pi3) za liječenje upalnih bolesti dišnih puteva
RS54476B1 (en) DERIVATIVES 1 - ((5-HETEROARYLTHIAZOL-2-IL) AMINOCARBONYL) PYROLIDINE-2-CARBOXAMIDE AS PHOSPHATIDYLINOSITOL 3-KINASE (PI3K) INHIBITORS USEFUL IN THE TREATMENT OF PROLIFERATIVE DISEASES
MX2009002239A (es) Derivados de 5-(2-furil)-1,3-tiazol util como inhibidores de fosfatidilinositol 3-cinasa.
IL189375A (en) Derivatives 1-Heterocyclicsulfonyl-3-Aminomethyl-5- (hetero-) aryl-1-h- Pyrol
EA200970233A1 (ru) Кандидатные агенты против инфекций
ATE396731T1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
MY148375A (en) Delta and epsilon crystal forms of imatinib mesylate
NO20084853L (no) Forbindelser som er agonister av muscarinreseptorer og som kan vaere effektive i behandling av smerte, Alzheimers sykdom og/eller schizofreni
HRP20050714B1 (hr) Aminoheteroarilni spojevi kao inhibitori proteinskih kinaza
ECSP045253A (es) Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa
BRPI0408068A (pt) derivados de 5-feniltiazol e seus usos como inibidores de pi3 cinase
UA99617C2 (ru) Производные пирролконденсированного азотсодержащего гетероцикла, их получение и фармацевтическое применение
RS52189B (en) 5-LIPOKSIGENAZA-ACTIVIRAJUĆEG PROTEINA (FLAP) INHIBITORIES
ATE442847T1 (de) Benzimidazol-derivate als mek-hemmer
RS50807B (sr) 3,11 b-cis-dihidrotetrabenazin za lečenje šizofrenije i drugih psihoza
GEP20084452B (en) Sulfonamide derivatives for the treatment of diseases
EA200801996A1 (ru) 2-замещенные производные 4-бензилфталазинонов в качестве гистаминовых h1- и h3-антагонистов
RS53138B (en) 4- [2- (4-METHYLPHENYLSULPHANYL) PHENYL] PIPERIDINE FOR THE TREATMENT OF INJURED INTENTION SYNDROME (IBS).
DE602006017574D1 (de) Als protein-kinase-inhibitoren nutzbare benzimidazole
EA200601391A1 (ru) Производные хинолина для применения в качестве микобактериальных ингибиторов
MX2022009874A (es) Inhibidores heterociclicos de peptidil arginina desiminasa 4 (pad4).
EA200901474A1 (ru) Соли [4-(6-фтор-7-метиламино-2,4-диоксо-1,4-дигидро-2н-хиназолин-3-ил)фенил]-5-хлортиофен-2-илсульфонилмочевины в различных кристаллических формах и фармацевтические композиции на их основе
ATE517644T1 (de) Mikrogelpartikel
DE602005010744D1 (de) Piperazinylpyridinderivate als mittel gegen adipositas
PE20090320A1 (es) Derivados de piperidina-amida